Top marks for Cherwell’s Redipor prepared microbial media products
Extensive range of ready-to-use culture media available in bottles and plates.
A recent customer satisfaction survey has affirmed that the vast majority would recommend Cherwell and its Redipor microbiological media products to a colleague. Value for money, excellent customer service and product quality were all key factors contributing to the very positive outcome of this survey. These results are evidenced by Redipor’s growing user base within the pharmaceutical and associated industries both domestically and across Europe. Therefore, to accommodate all customers, Cherwell has just released both UK and Euro versions of its 2018/19 Redipor Prepared Media price list, now available to download from Cherwell’s website.
Redipor prepared media products scored highly with customers in Cherwell’s recent survey to achieve an impressive Net Promoter Score of +76 (from a range of -100 to +100). Customer comments as to ‘Why Cherwell?’ included: ”The excellent service; great pricing; exceeding expectations with delivery times; helping us out in a crisis; flexibility by preparing bespoke media; pragmatic advice; and realistic timeframes. What more could anyone want?”
Meeting varying customer needs, such as for environmental monitoring, sterility testing and validation applications, the new Redipor price list details the extensive range of ready-to-use culture media available in bottles and plates. Cherwell provides a selection of the most commonly requested types, many of which are available from stock for next day delivery. In addition to those included in the price list, Cherwell offers many other bespoke products which are made to order with short lead times and small minimum order requirements. Discounts are available for high volume and standing orders.
“With customer satisfaction and ease of access in mind, we have laid out our new Redipor price list to enable straightforward reference of ordering information and products,” said Andrew Ramage, Cherwell’s Microbiology Product Specialist. “And if customers can't find exactly what they need, we’d like to hear from them as we frequently adapt to meet specific requirements, be it the media formulation, format, packaging or quantity. We are also very happy to provide rapid quotations and flexible delivery schedules.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.